Cidara Therapeutics Inc
CDTX62.905USD
+0.005+0.01%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
768.02MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Cidara Therapeutics Inc Unternehmen
Cidara Therapeutics, Inc. is a biotechnology company. The Company is developing targeted immunotherapies designed for patients facing serious diseases. The Company’s portfolio comprises various treatment and prevention paradigms, including drug-Fc conjugate (DFC) from its Cloudbreak platform targeting oncologic, viral and autoimmune diseases. The Company is focused on advancing Cloudbreak development programs, including its lead oncology candidate, CBO421, as well as advancing other pipeline assets. CBO421 is a development candidate targeting CD73 for the treatment of solid tumors. Its advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials. Its additional programs target multiple autoimmune indications.
Unternehmensinformationen
BörsenkürzelCDTX
Name des UnternehmensCidara Therapeutics Inc
IPO-datumApr 15, 2015
CEODr. Jeffrey L. (Jeff) Stein, Ph.D.
Anzahl der mitarbeiter38
WertpapierartOrdinary Share
GeschäftsjahresendeApr 15
Addresse6310 Nancy Ridge Dr Ste 101
StadtSAN DIEGO
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl92121-3209
Telefon18587526170
Websitehttps://www.cidara.com/
BörsenkürzelCDTX
IPO-datumApr 15, 2015
CEODr. Jeffrey L. (Jeff) Stein, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Frank L. Karbe
Mr. Frank L. Karbe
Chief Financial Officer
Chief Financial Officer
57.50K
--
Mr. Daniel D. (Dan) Burgess
Mr. Daniel D. (Dan) Burgess
Independent Chairman of the Board
Independent Chairman of the Board
150.00
--
Mr. Ryan Spencer
Mr. Ryan Spencer
Independent Director
Independent Director
--
--
Dr. Bonnie Bassler, Ph.D.
Dr. Bonnie Bassler, Ph.D.
Independent Director
Independent Director
--
--
Ms. Chrysa Mineo
Ms. Chrysa Mineo
Independent Director
Independent Director
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Brian Ritchie
Mr. Brian Ritchie
Investor Relations
Investor Relations
--
--
Mr. Theodore R. (Ted) Schroeder
Mr. Theodore R. (Ted) Schroeder
Independent Director
Independent Director
--
--
Mr. Shane Ward
Mr. Shane Ward
Chief Operating Officer, Chief Legal Officer, Company Secretary
Chief Operating Officer, Chief Legal Officer, Company Secretary
--
--
Dr. Josh Resnick, M.D., J.D.
Dr. Josh Resnick, M.D., J.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Frank L. Karbe
Mr. Frank L. Karbe
Chief Financial Officer
Chief Financial Officer
57.50K
--
Mr. Daniel D. (Dan) Burgess
Mr. Daniel D. (Dan) Burgess
Independent Chairman of the Board
Independent Chairman of the Board
150.00
--
Mr. Ryan Spencer
Mr. Ryan Spencer
Independent Director
Independent Director
--
--
Dr. Bonnie Bassler, Ph.D.
Dr. Bonnie Bassler, Ph.D.
Independent Director
Independent Director
--
--
Ms. Chrysa Mineo
Ms. Chrysa Mineo
Independent Director
Independent Director
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
RA Capital Management, LP
16.69%
Commodore Capital LP
5.83%
VR Adviser, LLC
5.21%
TCG Crossover Management, LLC
4.99%
Point72 Asset Management, L.P.
4.96%
Other
62.32%
Aktionäre
Aktionäre
Anteil
RA Capital Management, LP
16.69%
Commodore Capital LP
5.83%
VR Adviser, LLC
5.21%
TCG Crossover Management, LLC
4.99%
Point72 Asset Management, L.P.
4.96%
Other
62.32%
Aktionärstypen
Aktionäre
Anteil
Venture Capital
29.07%
Hedge Fund
24.64%
Investment Advisor
15.03%
Investment Advisor/Hedge Fund
4.77%
Individual Investor
1.12%
Research Firm
0.52%
Pension Fund
0.12%
Other
24.73%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
130
15.18M
75.27%
+7.25M
2025Q1
124
10.47M
53.54%
+2.71M
2024Q4
122
7.70M
70.35%
+1.07M
2024Q3
109
4.49M
61.04%
+771.77K
2024Q2
109
1.90M
39.70%
+56.88K
2024Q1
108
1.55M
384.06%
-209.94K
2023Q4
111
1.70M
37.69%
-299.58K
2023Q3
119
1.90M
42.77%
-451.34K
2023Q2
126
1.95M
43.98%
-451.51K
2023Q1
153
2.02M
47.21%
-214.92K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
RA Capital Management, LP
3.37M
16.69%
+2.27M
+207.97%
Jun 26, 2025
Commodore Capital LP
1.18M
5.83%
+1.18M
--
Jun 25, 2025
VR Adviser, LLC
1.05M
5.21%
+285.80K
+37.32%
Mar 31, 2025
TCG Crossover Management, LLC
1.01M
4.99%
--
--
Mar 31, 2025
Point72 Asset Management, L.P.
999.41K
4.96%
+885.56K
+777.80%
Apr 09, 2025
Adage Capital Management, L.P.
990.00K
4.91%
+620.05K
+167.60%
Mar 31, 2025
BVF Partners L.P.
924.64K
4.59%
-168.15K
-15.39%
Mar 31, 2025
Bain Capital Life Sciences Investors, LLC
703.08K
3.49%
--
--
Mar 31, 2025
Canaan Partners
703.08K
3.49%
+703.08K
--
Jul 19, 2024
Vivo Capital, LLC
684.28K
3.39%
+13.68K
+2.04%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Invesco Dorsey Wright SmallCap Momentum ETF
0.78%
iShares Micro-Cap ETF
0.15%
Avantis US Small Cap Equity ETF
0.05%
iShares Russell 2000 Value ETF
0.05%
Proshares Ultra Russell 2000
0.03%
ProShares UltraPro Russell2000
0.03%
Global X Russell 2000 ETF
0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.03%
ProShares Hedge Replication ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
Mehr Anzeigen
Invesco Dorsey Wright SmallCap Momentum ETF
Anteil0.78%
iShares Micro-Cap ETF
Anteil0.15%
Avantis US Small Cap Equity ETF
Anteil0.05%
iShares Russell 2000 Value ETF
Anteil0.05%
Proshares Ultra Russell 2000
Anteil0.03%
ProShares UltraPro Russell2000
Anteil0.03%
Global X Russell 2000 ETF
Anteil0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Anteil0.03%
ProShares Hedge Replication ETF
Anteil0.03%
Invesco RAFI US 1500 Small-Mid ETF
Anteil0.02%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
Datum
Art
Verhältnis
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
